Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)

  • Technology appraisal
  • TA436
  • Published: 
Download guidance (PDF)

Background

Roche has informed NICE that it does not intend to pursue reimbursement for this indication and, as such, will not be making an evidence submission to NICE for this indication.

NICE has therefore terminated this single technology appraisal.

  • National Institute for Health and Care Excellence (NICE)